Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C

This publication has 31 references indexed in Scilit:

• Lower activities of serum peptidases predict higher depressive and anxiety levels following interferon‐alpha‐based immunotherapy in patients with hepatitis C
  Acta Psychiatrica Scandinavica, 2004
• Interferon-alpha–induced changes in tryptophan metabolism
  Biological Psychiatry, 2003
• Adherence to combination therapy enhances sustained response in genotype-1–infected patients with chronic hepatitis C
  Gastroenterology, 2002
• Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy
  Molecular Psychiatry, 2002
• Interferon alpha (IFNα) and psychiatric syndromes
  Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2002
• Interferon-induced depression treated with citalopram.
  The Journal of Clinical Psychiatry, 2002
• Increased Depressive Ratings in Patients With Hepatitis C Receiving Interferon-α–Based Immunotherapy Are Related to Interferon-α–Induced Changes in the Serotonergic System
  Journal of Clinical Psychopharmacology, 2002
• Treatment with interferon-alpha (IFNα) of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFNα-induced depressive and anxiety symptoms and immune activation
  Molecular Psychiatry, 2001
• Neuropsychiatric Symptoms Associated With Hepatitis C and Interferon Alpha: A Review
  American Journal of Psychiatry, 2000
• Side Effects of Alpha Interferon
  Seminars in Liver Disease, 1989